ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $6,456,896 | -12.2% | 60,221 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $7,354,791 | +22.5% | 60,221 | +3.6% | 0.01% | +20.0% |
| Q3 2022 | $6,002,000 | +26.2% | 58,127 | +13.6% | 0.01% | +42.9% |
| Q2 2022 | $4,757,000 | -18.5% | 51,174 | +1.7% | 0.01% | -12.5% |
| Q1 2022 | $5,836,000 | +17.4% | 50,305 | +36.2% | 0.01% | +33.3% |
| Q4 2021 | $4,970,000 | -11.5% | 36,943 | +4.8% | 0.01% | -33.3% |
| Q3 2021 | $5,618,000 | +87.5% | 35,248 | +54.7% | 0.01% | +125.0% |
| Q2 2021 | $2,997,000 | +10.4% | 22,780 | +8.2% | 0.00% | 0.0% |
| Q1 2021 | $2,714,000 | -57.1% | 21,057 | -44.4% | 0.00% | 0.0% |
| Q4 2020 | $6,320,000 | +105.5% | 37,894 | +95.5% | 0.00% | -20.0% |
| Q3 2020 | $3,076,000 | +17.3% | 19,388 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,622,000 | +52.4% | 17,729 | +21.9% | 0.01% | +25.0% |
| Q1 2020 | $1,720,000 | -14.7% | 14,538 | +0.3% | 0.00% | +33.3% |
| Q4 2019 | $2,016,000 | +44.6% | 14,492 | 0.0% | 0.00% | +50.0% |
| Q3 2019 | $1,394,000 | – | 14,492 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |